High-risk early HR-positive breast cancer

What changed: High-risk early HR-positive breast cancer

Cancer page →

Every dated change on the records linked to High-risk early HR-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result9Milestone10This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHigh-risk early HR-positive breast cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 2

2023 · 2

2021 · 1

2021Trial resultOlympiA
OlympiA reported
iDFS HR 0.

2020 · 4

2018 · 2

2016 · 2

2014 · 2

2013 · 1

2013MilestoneTamoxifen
ATLAS: ten years of tamoxifen beats five
A milestone in how this cancer is treated.

2004 · 1

2004MilestoneLetrozole (and other aromatase inhibitors)
MA.17: letrozole after five years of tamoxifen reduces late recurrence
A milestone in how this cancer is treated.

1998 · 1

1998MilestoneTamoxifen
EBCTCG overview: five years of tamoxifen cuts recurrence and death
A milestone in how this cancer is treated.

1977 · 1

1977MilestoneTamoxifen
Tamoxifen approved
A milestone in how this cancer is treated.